|
|
|
|
|
|
Sponsored by: |
Genzyme |
Information provided by: | Genzyme |
ClinicalTrials.gov Identifier: | NCT00417469 |
The purpose of this research study is to compare subject comfort during and after injection with NADGL and Captique® Injectable Gel, in the nasolabial folds. Captique® is an FDA-approved product without lidocaine and is manufactured by Genzyme Biosurgery (Ridgefield, NJ). NADGL is a new product (not FDA approved) with lidocaine and is also manufactured by Genzyme Biosurgery. We do not know which of these treatments results in less pain during and after injection. The safety of NADGL is also being studied.
Condition | Intervention | Phase |
Facial Wrinkles |
Device: NADGL |
Phase III |
Drug Information available for: | Lidocaine |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Single-Blind, Randomized, Single-Center Evaluation of Procedural and Post Procedural Pain Experienced With Injections of NADG With Lidocaine Injectable Gel as Compared to Captique® Injectable Gel in Subjects Undergoing Cutaneous Correction of Nasolabial Folds |
Estimated Enrollment: | 45 |
Study Start Date: | January 2007 |
45 subjects are planned; a portion of these subjects will have skin of color
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | NADGL00106 |
First Received: | December 28, 2006 |
Last Updated: | June 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00417469 |
Health Authority: | United States: Food and Drug Administration |
|